Express Scripts Holding Co. is dropping coverage of a diabetes drug produced by Valeant Pharmaceuticals International Inc., the latest move in the ongoing price war between drug makers and pharmacy benefit managers.
Express Scripts said in a post on its web site that it was excluding Valeant’s Glumetza diabetes drug from its formulary as of Monday, when a generic version of the drug becomes available in the U.S. According to Express Scripts, Valeant raised the price for Glumetza by more than 800 percent in 2015.
Last fall, Express Scripts was among three pharmacy benefit managers that said they would cut ties with Philidor RX Services, a pharmacy with which Valeant Phamaceuticals has partnered. Philidor had come under scrutiny for its aggressive tactics to ensure pharmacy-benefit managers use Valeant drugs over lower-cost alternatives.
Read more: St. Louis Business Journal